Navigation Links
Neuro Kinetics Presenting New Balance & Dizziness Research at American Balance Society Conference
Date:3/3/2011

PITTSBURGH, March 3, 2011 /PRNewswire/ -- Neuro Kinetics, Inc. (NKI) (www.neuro-kinetics.com), manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, said today that it co-presented two research studies at this week's American Balance Society conference meeting in Scottsdale, Arizona.

The research continues the company's push to expand and refine the clinical testing that can be conducted with its medical equipment in the diagnosis of balance and dizziness conditions. Studies suggest that 50 percent of all individuals suffer from balance and equilibrium conditions during their lifetimes. The elderly are particularly vulnerable as falls can lead to devastating life-threatening consequences.

The first paper for the American Balance Society conference detailed the collection of normative patient data using video oculography (VOG) based eye tracking with a rotational (Barany) chair. The paper -- co-authored by Dr. Alexander Kiderman, NKI's chief technology officer, and Dr. Jorge Gonzalez, a professor in the Department of Audiology and Speech Pathology at Bloomsburg University – reported on the data collection work at Bloomsburg.

Data was collected for four types of rotational tests: Sinusoidal Harmonic Acceleration (SHA), Step Testing, Visual Enhancement (VVOR) and Visual Suppression (VF).

(Read abstract here.)  - link to http://www.neuro-kinetics.com/news_2011abs2.aspx

The second paper focused on comparing static and dynamic tests of Subjective Visual Vertical (SVV) which measure the deviation between a patient's vertical perception and actual gravitational perception.  The study addresses a question in the testing for balance and dizziness disorders about whether or not to consider the static SVV results during the dynamic SVV test.

The paper was co-authored by Dr. Kiderman; along with Dr. Howard Mango and Dr. Cara Makuta, both of the Newport Mesa Audiology Balance & Ear Institute in Newport, California, where the research was conducted.

(Read abstract here.) - link to http://www.neuro-kinetics.com/news_2011abs2.aspx

"We're delighted to be able to offer important new research to the community of balance specialists from around the world," said J. Howison Schroeder, NKI president and CEO. "Great strides are being made in the understanding of balance and equilibrium disorders and we're proud to be a leader in expanding the knowledge base."

ABOUT NEURO KINETICS, INC.

Neuro Kinetics, Inc. (NKI) is the world leader in eye-tracking technology and non-invasive neuro-otologic diagnostic testing.Central to its product mix and technological advances is the premise that the eye is the portal to the brain.  Research has shown the detection of abnormal eye reflexes can indicate the presence of more than 200 diseases and medical conditions. 

For more than 25 years, NKI has supplied comprehensive neuro-otologic diagnostic tools to audiologists, ENT's, neuro-otologists, neuro-ophthalmologists and neurologists around the globe. The company's patented products include the I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG (Video Nystagmography) and I-Portal® VOG (Video Oculography), along with related accessories, software, training and support services. MEDIA CONTACTJohn BuckmanBuckman Communications, for Neuro Kinetics, Inc.+ 1 412-381-2900 or jbuckman@buckman.biz
'/>"/>

SOURCE Neuro Kinetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
5. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
6. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
9. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
10. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
11. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 Treato ... on healthcare, announced today that it has been named ... Cool Vendor in Life Sciences, 2016, Stephen ...  The report focuses on life-science- oriented analytics, algorithms and ... patients and doctors, confirm medication ingestion, and analyze unstructured ...
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
Breaking Medicine Technology:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... of a growth round of funding led by Eastside Partners, with participation from ... company’s rapidly growing customer base and accelerate its technology and product roadmap. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... to promote their animal line of probiotics, Petbiotics ™, as they fondly ... turnout of animal rescue groups networking for their non-profit organizations. Animal rescues across ...
(Date:4/29/2016)... ... 29, 2016 , ... Coalition Duchenne, a Newport Beach, California ... Duchenne research, participated in the April 25 U.S. Food and Drug Administration advisory ... The meeting at the Marriott Conference Center in Hyattsville, Maryland was attended by ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... data for 2014. Each year, reproductive endocrinologists are required to report in ... main organization of professionals dedicated to the practice of assisted reproductive technologies in ...
Breaking Medicine News(10 mins):